Specialty Pharmaceuticals / Transdermal Drug Delivery
Strategic Profile
Noven's commercialized products and product development activities are principally focused in the areas of women's health and mental health, including ADHD and schizophrenia. The company maintains state-of-the art, FDA-approved transdermal manufacturing facilities in Miami with capacity to produce several hundred million patches per year. Noven operates with over 300 colleagues at locations in Miami, Florida and Jersey City, New Jersey.
Cyborg Score Rationale
Noven operates as a focused specialty pharmaceutical company with proprietary transdermal delivery technology and established manufacturing infrastructure. The backing of Japanese parent Hisamitsu provides capital and global scale advantages. However, private subsidiary status limits transparency, and dependence on a single parent company presents execution risk.
Top Insights
Noven broke ground in April 2026 on a new state-of-the-art Quality Control Laboratory Building exceeding 24,000 sqft, designed to increase output capacity to meet growing patient demands.
Noven commercializes products through Noven Therapeutics, LLC, with Grove Pharmaceuticals serving as its generic division.
Strategic focus on transdermal delivery innovation in high-demand therapeutic areas (women's health and psychiatry) with established brand franchises including XELSTRYM, SECUADO, and COMBIPATCH.
Noven serves as Hisamitsu's platform for US prescription pharmaceuticals, helping bring patch therapy benefits to the world.
Named Competitors
Pfizer — Large integrated pharmaceutical company with broad therapeutic portfolio
Hisamitsu Pharmaceutical — Parent company and world's largest transdermal patch manufacturer
Mylan/Viatris — Generic and specialty pharma competitor with psychiatric products
Recent Developments
(April 2026) Broke ground on new state-of-the-art Quality Control Laboratory Building with 24,000+ sqft capacity expansion
(October 2022) Presented data on transdermal dextroamphetamine wear-times and pediatric-to-adult efficacy extrapolation
(October 2019) FDA approval of Secuado (asenapine) transdermal system for schizophrenia treatment
Open the full interactive Noven Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.